Feed / ITGR

Integer Holdings Corporation

ITGR

Healthcare · 126.21 +0.2% today

Isolated · not yet confirmedMarket checked 11 Sept, 12:10 GMT-4

Market read

Integer Holdings Corporation's current read is isolated; its market group is not confirming.

The latest filing evidence is available. 0 of 14 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.

What changed
  • Revenue decreased 2.6% versus the comparable filing period.
Company+0.2% todayVolume comparison unavailable
Market group0 of 14 activeMixed Sector Exposure · unavailable
Disclosed network0 of 1 confirmingNo filing-linked name is confirming now
What would change this read
  • Lower production volumes reduced fixed-cost absorption and contributed to the gross-profit decline.

Invalidation: The isolated read changes if ITGR's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Medical Devices

The latest filing evidence is available. 0 of 14 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 1 directly disclosed connection is confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges
  • Revenue decreased 2.6% versus the comparable filing period.
  • Operating margin fell 5.0 percentage points.
  • Net income decreased 36.2% versus the comparable filing period.
What would clarify the read
  • Lower production volumes reduced fixed-cost absorption and contributed to the gross-profit decline.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations327
Usable filing statements89
Verified relationships1
Evidence supporting the case
  • Latest annual revenue changed +8.0% year over year.
  • Operating cash flow covered net income at 1.91x in the latest annual period.
  • Foreign exchange has repeated favorable evidence across 5 filings.
  • Demand and volume has repeated favorable evidence across 3 filings.
  • Product pipeline and R&D has repeated favorable evidence across 3 filings.
Evidence challenging the case
  • Net margin changed -1.4 percentage points in the latest annual period.
  • Credit and interest rates has repeated adverse evidence across 5 filings.
Questions before a position
  • P/E is 46% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 10, 2026

126.10
6m+47.5%12m+19.5%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$1.2B+13.8%$2.91+0.4%
2022-12-31$1.3B+9.0%$1.99+0.3%
2023-12-31$1.6B+16.9%$2.69+1.2%
2024-12-31$1.7B+10.3%$3.36+5.6%
2025-12-31$1.9B+8.0%$2.89-0.2%

What management says matters

Persistent and emerging business drivers

Credit and interest ratesnegative · 5 filings
Cash provided by financing activities for the first six months of 2025 was primarily the net proceeds from the issuance of our 2030 Convertible Notes of $977.5 million, which was partially offset by a $71.0 million purchase of capped call options associated w…
10-Q · Aug 4, 2026
Foreign exchangepositive · 5 filings
Foreign currency exchange rate fluctuations increased C&V sales for the second quarter and first six months of 2026 by $0.3 million and $1.6 million, in comparison to the corresponding periods in 2025, primarily due to U.S.
10-Q · Aug 4, 2026
Demand and volumepositive · 3 filings
The increase in C&V sales for 2025 was driven by strong growth from new product ramps in electrophysiology, contributions from acquisitions, and strong demand in neurovascular.
10-K · Feb 23, 2026
Product pipeline and R&Dpositive · 3 filings
The increase in C&V sales for 2025 was driven by strong growth from new product ramps in electrophysiology, contributions from acquisitions, and strong demand in neurovascular.
10-K · Feb 23, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales 2.4× · EV/sales 3.1×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

126.21+0.2% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 12:10 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for ITGR. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Latest filing assessment

The latest filing shows material pressure

10-Q filed 2026-08-04 against the comparable filing from 2025-07-24.

cautious
OperationscautiousEvidence score -4
liquidityneutralEvidence score 0
valuationmixed

Capital and cash conversion

Inventory built faster than revenue

watch

Inventory growth exceeded revenue growth and inventory intensity increased.

Capital spending YoY
+5.5%
Capital spending / revenue
+5.2%
Free-cash-flow margin
+4.2%
FCF margin change
+0.8 pts

Capex, revenue, and operating cash flow are matched to the same reported duration. Reported accounting context, not a forecast or trading recommendation.

What improved

No thresholded improvement was identified.

What weakened

  • Revenue decreased 2.6% versus the comparable filing period.
  • Operating margin fell 5.0 percentage points.
  • Net income decreased 36.2% versus the comparable filing period.

Filing receipts

For additional information regarding legal proceedings pending against us, refer to Note 10, “Commitments and Contingencies,” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report. (b) Contract services expense increased primarily due to higher software costs from information technology enhancements.

Foreign currency exchange rate fluctuations increased C&V sales for the second quarter and first six months of 2026 by $0.3 million and $1.6 million, in comparison to the corresponding periods in 2025, primarily due to U.S. dollar fluctuations relative to the Euro.

Other Markets sales for the second quarter and first six months of 2026 decreased $7.6 million, or 43%, and $16.1 million or 45%, respectively, versus the comparable 2025 periods, primarily due to the Portable Medical Exit.

Historical filing backfill generated after the original filing window. It is not part of Jodie's live track record.

Business ecosystem

The relationships behind ITGR

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depended on by

TELTE Connectivity plccompetitorNov 10, 2025

The Industrial Solutions segment competes primarily against Amphenol, Hubbell, Carlisle Companies, Integer Holdings, Molex, Omron, JST, and Korea Electric Terminal (KET).

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

ITGR is currently a Follower in the organic co-movement group Mixed Sector Exposure. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.